➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Boehringer Ingelheim
Colorcon
Mallinckrodt
Johnson and Johnson

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Claims for Patent: 5,514,370

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 5,514,370
Title: High dosage topical forms of collagenase
Abstract:This invention provides pharmaceutical compositions for topical application containing high concentrations of the enzyme collagenase in non-aqueous excipients. The invention also provides a particular excipient, dextran, which is especially useful for admixture with collagenase and which can also be used to advantage with other pharmaceutically active materials.
Inventor(s): Stern; Harold (Baldwin Harbor, NY), Yee; David (Oceanside, NY)
Assignee: Advance Biofactures of Curacao, N.V. (Brievengat, AN)
Application Number:08/335,261
Patent Claims:1. A method of treating a wound or other condition of the body subject to topical treatment which comprises applying thereto a composition consisting essentially of an intimate physical admixture of a non-aqueous excipient and at least about 1,500 ABC units of collagenase per gram of excipient.

2. A method according to claim 1, wherein the composition is in the form of an ointment.

3. A method according to claim 2, wherein the excipient is petrolatum.

4. A method according to claim 2, wherein the composition contains from about 1,500 to about 5,000 ABC units of collagenase per gram of excipient.

5. A method according to claim 1, wherein the excipient is a dry powder.

6. A method according to claim 5, wherein the excipient is lactose.

7. A method according to claim 5, wherein the excipient is a mixture of polymyxin B sulfate and bacitracin in powder form.

8. A method according to claim 5, wherein the composition contains from about 2,500 to about 10,000 ABC units of collagenase per gram of excipient.

9. A method of treating a wound or other condition of the body subject to topical treatment which comprises applying thereto a composition consisting essentially of a dry powdered intimate physical admixture of dextran as excipient and in excess of 5,000 ABC units of collagenase per gram of dextran.

10. A method according to claim 5, wherein the composition contains at least about 8,000 ABC units of collagenase per gram of excipient.

11. A method according to claim 1, wherein the composition also contains an antibiotic or antiseptic.

12. A method according to claim 1, wherein the condition is a burn.

13. A method according to claim 1, wherein the condition is a decubitus ulcer.

14. A method of treating a wound or other condition of the body subject to topical treatment which comprises applying thereto a composition comprising an intimate physical admixture of a non-aqueous excipient and at least about 1,500 ABC units of collagenase per gram of excipient, said collagenase not being bound to the excipient by an added chemical binding agent.

15. A method according to claim 14, wherein the composition is in the form of an ointment.

16. A method according to claim 15, wherein the excipient is petrolatum.

17. A method according to claim 14, wherein the excipient is a dry powder.

18. A method according to claim 17, wherein the excipient is lactose.

19. A method according to claim 17, wherein the excipient is a mixture of polymyxin B sulfate and bacitracin in powder form.

20. A method according to claim 17, wherein the excipient is dextran.

21. A method according to claim 14, wherein the condition is a burn.

22. A method according to claim 14, wherein the condition is a decubitus ulcer.

23. A method for treating a wound or other condition of the body subject to topical treatment which comprises applying thereto a composition comprising a dry powdered intimate physical admixture of water-soluble dextran and from about 0.01 to about 30 weight per cent of a pharmaceutical suited for topical application, said pharmaceutical not being bound to the dextran by an added chemical binding agent.

24. A method according to claim 23, wherein said pharmaceutical is collagenase in an amount from about 100 to about 10,000 ABC units per gram of dextran.

25. A method according to claim 23, wherein said pharmaceutical is an enzyme.

26. A method according to claim 23, wherein said pharmaceutical is an antibiotic.

27. A method for treating a wound or other condition of the body subject to topical treatment which comprises applying thereto a composition consisting essentially of a dry powdered intimate physical admixture of water-soluble dextran and from about 0.01 to about 30 weight per cent of a pharmaceutical suited for topical application.

28. A method according to claim 27, wherein said pharmaceutical is collagenase in an amount from about 100 to about 10,000 ABC units per gram of dextran.

29. A method according to claim 27, wherein said pharmaceutical is an enzyme.

30. A method according to claim 27, wherein said pharmaceutical is an antibiotic.

Details for Patent 5,514,370

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Smith And Nephew SANTYL collagenase OINTMENT;TOPICAL 101995 001 1965-06-04 ⤷  Free Forever Trial Advance Biofactures of Curacao, N.V. (Brievengat, AN) 2011-11-20 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Boehringer Ingelheim
AstraZeneca
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.